Trial Profile
A Randomized, Double-blind, Placebo Controlled, Crossover Study to Assess Safety and Tolerability, Pharmacokinetics, and Explore Pharmacodynamics of TAP311 in Patients With Mixed Dyslipidaemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2013
Price :
$35
*
At a glance
- Drugs TAP 311 (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jul 2012 New trial record